Palleon Pharmaceuticals Overview
- Founded
- 2015
- Status
- Private
- Employees
- 19
- Latest Deal Type
- Series B
- Latest Deal Amount
- $100M
- Investors
- 7
Palleon Pharmaceuticals General Information
Description
Developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer. The company's biotechnology platform integrates technologies and insights from scientific leaders all over the world in the fields of glycoscience and human immunology to create a novel approach to treating cancer by targeting multiple immune cell types, providing physicians with a wider range of rational combination therapies to treat cancer and tackle resistance to first-generation immuno-oncology agents.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
- 266 Second Avenue
- 2nd Floor
- Waltham, MA 02451
- United States
+1 (857) 000-0000
Palleon Pharmaceuticals Timeline
Palleon Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 16-Sep-2020 | $100M | 00000 | 00000 | Completed | Pre-Clinical Trials |
| 2. Early Stage VC (Series A) | 04-Oct-2017 | 000.00 | 000.00 | 000.00 | Completed | Pre-Clinical Trials |
| 1. Accelerator/Incubator | Completed | Pre-Clinical Trials |
Palleon Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00.00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
| Series A | 00,000,000 | 00.000000 | 00.00 | 00 | 00 | 00 | 00 | 00.000 |
Palleon Pharmaceuticals Executive Team (6)
Palleon Pharmaceuticals Board Members (15)
| Name | Representing | Role | Since |
|---|---|---|---|
| Deepa Pakianathan Ph.D | Palleon Pharmaceuticals | Board Member | 000 0000 |
| Eric Xiao | Matrix Capital Management | Board Member | 000 0000 |
| James Broderick MD | Palleon Pharmaceuticals | Co-Founder, Chief Executive Officer, President & Board Member | 000 0000 |
| Jayson Punwani Ph.D | Self | Board Member | 000 0000 |
| Karan Takhar | Matrix Capital Management | Board Member | 000 0000 |
Palleon Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialPalleon Pharmaceuticals Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Citadel (Hedge Fund) | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Matrix Capital Management | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| AbbVie Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Pfizer Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| SR One | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |